Examine the challenges India's drug regulatory framework faces in responding to international carcinogenicity reclassifications of essential medicines.

The IARC, WHO's specialised cancer agency at Lyon, has placed hydrochlorothiazide, voriconazole and tacrolimus in Group 1 — "carcinogenic to humans" in Monographs Volume 137 [1]. All three are on the WHO Model List of Essential Medicines [2], and India's response exposes structural strains in its drug regulation.

Translating hazard into risk

• IARC performs hazard identification, not risk quantification, and does not advise stopping treatment [3]. India lacks a standing protocol to convert such a finding into dose- and duration-specific prescribing guidance.
• Risk-communication dilemma: headline reporting of "carcinogenic" can trigger sudden discontinuation of antihypertensives, raising stroke and cardiac risk.

Institutional and federal capacity

• Revisiting an already-approved molecule needs DTAB advice and amendment of rules under the Drugs and Cosmetics Act, 1940 — a slow, consultative route [4]; the central–state split in licensing manufacture and sale further fragments enforcement.
• Shortage of drug inspectors and testing laboratories means India generates little independent carcinogenicity evidence and largely imports foreign conclusions.

Weak long-term surveillance

• The Pharmacovigilance Programme of India captures acute adverse drug reactions [5], not long-latency outcomes like cancer; prescription data is not routinely linked to the National Cancer Registry Programme.

Access–equity trade-off

• Hydrochlorothiazide is cheap and mass-prescribed; under NP-NCD over 38 crore hypertension screenings have been conducted [6], so substitution at scale carries cost and adherence consequences.
• Dermatologists note higher photo-carcinogenic exposure among coastal, hilly and North-Eastern populations, an equity dimension in labelling and counselling [7].

The challenge is therefore less scientific than institutional — converting international hazard signals into calibrated, timely domestic action. A standing CDSCO–ICMR mechanism to review IARC evaluations, risk-proportionate labelling with periodic benefit–risk reassessment, linkage of pharmacovigilance data with cancer registries, and clear messaging that therapy continues under medical advice would close the gap. Such responsiveness strengthens the right to health under Article 21 and India's SDG-3 commitments.